Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin

<div><p>The tissue distribution and function of hemoglobin or myoglobin are well known; however, a newly found cytoglobin (CYGB), which also belongs to the globin family, remains to be characterized. To assess its expression in human malignancies, we sought to screen a number of cell lines originated from many tissues using northern blotting and real time PCR techniques. Unexpectedly, we found that several, but not all, melanoma cell lines expressed CYGB mRNA and protein at much higher levels than cells of other origins. Melanocytes, the primary origin of melanoma, also expressed CYGB at a high level. To verify these observations, immunostaining and immunoblotting using anti-CYGB antibody were also performed. Bisulfite-modified genomic sequencing revealed that several melanoma cell lines that abrogated CYGB expression were found to be epigenetically regulated by hypermethylation in the promoter region of <i>CYGB</i> gene. The RNA interference-mediated knockdown of the CYGB transcript in CYGB expression-positive melanoma cell lines resulted in increased proliferation <i>in vitro</i> and <i>in vivo</i>. Flow cytometric analysis using 2′-, 7′-dichlorofluorescein diacetate (DCFH-DA), an indicator of reactive oxygen species (ROS), revealed that the cellular ROS level may be involved in the proliferative effect of CYGB. Thus, CYGB appears to play a tumor suppressive role as a ROS regulator, and its epigenetic silencing, as observed in CYGB expression-negative melanoma cell lines, might function as an alternative pathway in the melanocyte-to-melanoma transition.</p></div

Sequencing histograms for the CpG island of the CYGB promoter region.

<p>Of the 24 CpG sites known to be methylated in the CYGB promoter region, 9 sites analyzed for methylation are shown. Cytosines methylated in A375 <b>(B)</b> are underlined. The corresponding cytosines are entirely unmethylated in melanocytes <b>(A)</b> and G361 <b>(C)</b>, resulting in the sequence “TpG” after bisulfite treatment.</p

CYGB protein is overexpressed in melanocytes and some of its malignant offspring.

<p><b>(A)</b> Immunoblot analysis of CYGB protein (indicated by an arrow) in NHDF, keratinocytes and melanocytes from skin and 8 melanoma cell lines (WM35 to HS294T). The image was obtained using ImageQuant LAS 3000 with an exposure time of 15 sec. The minor band, possibly a degradation product, is observed below the major band, which is prominent in melanocytes. The molecular mass marker (kDa) is given on the left side. β-actin was used as a loading control. <b>(B)</b> Immunohistochemical analysis of formalin-fixed, paraffin-embedded human normal skin using PNL2 (melanocyte marker) and CYGB antibodies. Two different regions (a) and (b) stained using each antibody are shown: (a) 4 × magnification, scale bar = 100 μm. (b) 20× magnification, scale bar  = 10 μm.</p

<i>CYGB</i>-knocked down melanoma cells increase proliferation.

<p><b>(A)</b> Immunoblot data for C32TG and G361 cells transfected with CYGB siRNA or control siRNA. β-actin was used as a loading control. <b>(B)</b> Cellular proliferation pattern for G361 and C32TG cells transfected with CYGB siRNA (si_CYGB) and control siRNA (si_Control). The MTT analysis was performed daily (1d to 4d) post-transfection. The value represents the mean from three independent experiments; OD value, 570 nm. bars, SEM. * <i>P</i><0.05, ** <i>P</i><0.01. <b>(C)</b> Growth analysis of xenografted G361 tumors in nude mice. G361 cells expressing shRNA against CYGB or control shRNA were subcutaneously implanted into the interscapular region of five female mice. Tumor size was measured at the indicated time points. Bars, SEM. * <i>P</i><0.05.</p

CYGB protects G361 cells from H₂O₂-induced cell death.

<p>A flow cytometric analysis was performed to determine the ROS level <b>(A)</b> and apoptosis <b>(B)</b> in G361 cells transfected with a CYGB-siRNA or a control-siRNA. In <b>(A)</b>, 2′-, 7′-dichlorofluorescein diacetate (DCFH-DA) was used. CYGB-knocked down G361 cells treated with 3 mM N-acetyl-L-cystein (NAC) were also compared. <b>(B)</b> Annexin V and PI staining was done after exposure of the cells to 100 μM H₂O₂ for 0 h (−) or 24 h (+). At an early stage of apoptosis the cells bind to Annexin V while still excluding PI. At a late stage of apoptosis they bind to Annexin V and stain brightly with PI. (a) Control-siRNA-transfected, and (b) CYGB-siRNA-transfected G361 cells.</p

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC - supplementary material

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC: plain language summary of publication </p

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC - supplementary material

infographic of: HERTHENA-Lung01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR-Mutated NSCLC</p

Image_3_The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.jpeg

IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of cancer types.MethodsWe retrospectively analyzed clinical data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless of treatment line. The concentrations of sPD-1 and sPD-L1 were measured with a fully automated immunoassay (HISCL system).ResultsThe study subjects comprised patients with head and neck cancer (n = 50), urothelial cancer (n = 42), renal cell cancer (n = 37), gastric cancer (n = 20), esophageal cancer (n = 10), malignant pleural mesothelioma (n = 6), or microsatellite instability-high tumors (n = 6). High or low levels of sPD-1 or sPD-L1 were not significantly associated with progression-free survival (PFS) or overall survival (OS) for PD-1 blockade in the entire study population. Comparison of treatment outcomes according to combinations of high or low sPD-1 and sPD-L1 levels, however, revealed that patients with low sPD-1 and high sPD-L1 concentrations had a significantly poorer PFS (HR of 1.79 [95% CI, 1.13–2.83], p = 0.01) and a tendency toward poorer OS (HR of 1.70 [95% CI, 0.99–2.91], p = 0.05) compared with all other patients.ConclusionOur findings suggest that the combination of low sPD-1 and high sPD-L1 levels is a potential negative biomarker for PD-1 blockade therapy.</p

Image_2_The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.jpeg

IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of cancer types.MethodsWe retrospectively analyzed clinical data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless of treatment line. The concentrations of sPD-1 and sPD-L1 were measured with a fully automated immunoassay (HISCL system).ResultsThe study subjects comprised patients with head and neck cancer (n = 50), urothelial cancer (n = 42), renal cell cancer (n = 37), gastric cancer (n = 20), esophageal cancer (n = 10), malignant pleural mesothelioma (n = 6), or microsatellite instability-high tumors (n = 6). High or low levels of sPD-1 or sPD-L1 were not significantly associated with progression-free survival (PFS) or overall survival (OS) for PD-1 blockade in the entire study population. Comparison of treatment outcomes according to combinations of high or low sPD-1 and sPD-L1 levels, however, revealed that patients with low sPD-1 and high sPD-L1 concentrations had a significantly poorer PFS (HR of 1.79 [95% CI, 1.13–2.83], p = 0.01) and a tendency toward poorer OS (HR of 1.70 [95% CI, 0.99–2.91], p = 0.05) compared with all other patients.ConclusionOur findings suggest that the combination of low sPD-1 and high sPD-L1 levels is a potential negative biomarker for PD-1 blockade therapy.</p

Image_1_The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.jpeg

IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of cancer types.MethodsWe retrospectively analyzed clinical data from 171 patients with advanced solid tumors who received nivolumab or pembrolizumab monotherapy regardless of treatment line. The concentrations of sPD-1 and sPD-L1 were measured with a fully automated immunoassay (HISCL system).ResultsThe study subjects comprised patients with head and neck cancer (n = 50), urothelial cancer (n = 42), renal cell cancer (n = 37), gastric cancer (n = 20), esophageal cancer (n = 10), malignant pleural mesothelioma (n = 6), or microsatellite instability-high tumors (n = 6). High or low levels of sPD-1 or sPD-L1 were not significantly associated with progression-free survival (PFS) or overall survival (OS) for PD-1 blockade in the entire study population. Comparison of treatment outcomes according to combinations of high or low sPD-1 and sPD-L1 levels, however, revealed that patients with low sPD-1 and high sPD-L1 concentrations had a significantly poorer PFS (HR of 1.79 [95% CI, 1.13–2.83], p = 0.01) and a tendency toward poorer OS (HR of 1.70 [95% CI, 0.99–2.91], p = 0.05) compared with all other patients.ConclusionOur findings suggest that the combination of low sPD-1 and high sPD-L1 levels is a potential negative biomarker for PD-1 blockade therapy.</p